262 related articles for article (PubMed ID: 12766081)
1. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target.
McGuire PG; Jones TR; Talarico N; Warren E; Das A
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2736-42. PubMed ID: 12766081
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Das A; Boyd N; Jones TR; Talarico N; McGuire PG
Arch Ophthalmol; 2004 Dec; 122(12):1844-9. PubMed ID: 15596589
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression.
Colombo ES; Menicucci G; McGuire PG; Das A
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1793-800. PubMed ID: 17389513
[TBL] [Abstract][Full Text] [Related]
4. A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes.
Navaratna D; Menicucci G; Maestas J; Srinivasan R; McGuire P; Das A
FASEB J; 2008 Sep; 22(9):3310-7. PubMed ID: 18559877
[TBL] [Abstract][Full Text] [Related]
5. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
6. Regulation and role of urokinase plasminogen activator in vascular remodelling.
Tkachuk V; Stepanova V; Little PJ; Bobik A
Clin Exp Pharmacol Physiol; 1996 Sep; 23(9):759-65. PubMed ID: 8911711
[TBL] [Abstract][Full Text] [Related]
7. Asbestos upregulates expression of the urokinase-type plasminogen activator receptor on mesothelial cells.
Perkins RC; Broaddus VC; Shetty S; Hamilton S; Idell S
Am J Respir Cell Mol Biol; 1999 Nov; 21(5):637-46. PubMed ID: 10536123
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy.
Basu A; Menicucci G; Maestas J; Das A; McGuire P
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4974-81. PubMed ID: 19443721
[TBL] [Abstract][Full Text] [Related]
9. Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases.
Datta A; Kitson RP; Xue Y; al-Atrash G; Mazar AP; Jones TR; Goldfarb RH
In Vivo; 2002; 16(6):451-7. PubMed ID: 12494889
[TBL] [Abstract][Full Text] [Related]
10. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
11. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
12. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
13. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.
Rakic JM; Lambert V; Munaut C; Bajou K; Peyrollier K; Alvarez-Gonzalez ML; Carmeliet P; Foidart JM; Noël A
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1732-9. PubMed ID: 12657615
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo inhibition of proangiogenic retinal phenotype by an antisense oligonucleotide downregulating uPAR expression.
Lulli M; Cammalleri M; Granucci I; Witort E; Bono S; Di Gesualdo F; Lupia A; Loffredo R; Casini G; Dal Monte M; Capaccioli S
Biochem Biophys Res Commun; 2017 Aug; 490(3):977-983. PubMed ID: 28666875
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Gondi CS; Lakka SS; Dinh DH; Olivero WC; Gujrati M; Rao JS
Clin Cancer Res; 2007 Jul; 13(14):4051-60. PubMed ID: 17634529
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
17. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization.
Satofuka S; Ichihara A; Nagai N; Koto T; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Itoh H; Oike Y; Ishida S
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):422-9. PubMed ID: 17197563
[TBL] [Abstract][Full Text] [Related]
18. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.
Guo Y; Higazi AA; Arakelian A; Sachais BS; Cines D; Goldfarb RH; Jones TR; Kwaan H; Mazar AP; Rabbani SA
FASEB J; 2000 Jul; 14(10):1400-10. PubMed ID: 10877833
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
20. Angiopoietin/Tek interactions regulate mmp-9 expression and retinal neovascularization.
Das A; Fanslow W; Cerretti D; Warren E; Talarico N; McGuire P
Lab Invest; 2003 Nov; 83(11):1637-45. PubMed ID: 14615417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
